Cardiovascular Disease and Breast Cancer: Where These Entities Intersect A Scientific Statement From the American Heart Association

@article{Mehta2018CardiovascularDA,
  title={Cardiovascular Disease and Breast Cancer: Where These Entities Intersect A Scientific Statement From the American Heart Association},
  author={Laxmi S. Mehta and K. Watson and A. Barac and T. Beckie and V. Bittner and S. Cruz-Flores and S. Dent and Lavanya Kondapalli and B. Ky and Tochukwu M. Okwuosa and I. Pi{\~n}a and A. Volgman},
  journal={Circulation},
  year={2018},
  volume={137},
  pages={e30–e66}
}
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women’s health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Additionally, current breast cancer treatments can have a negative impact on cardiovascular health (eg, left ventricular dysfunction, accelerated CVD), and for women with pre-existing CVD, this might influence cancer treatment decisions by both… Expand
Cardiovascular Disease among Breast Cancer Survivors
TLDR
Of particular concern is whether patients with hypertension, hypercholesterolemia, and diabetes are receiving appropriate therapy to reduce their cardiovascular risk and prevent morbidity and mortality from adverse cardiovascular events among breast cancer survivors. Expand
Management of Cardiovascular Disease in Women With Breast Cancer
TLDR
A cardio-oncology team-based approach to cardiovascular assessment and management of patients with BC from diagnosis through treatment and in survivorship is provided and current guideline recommendations apply to clinical cardiology and oncology questions. Expand
Breast Cancer and Cardiovascular Disease: Defining the Role of Physical Therapists
TLDR
A call to action is delivered to physical therapists to adequately assess the cardiopulmonary system for all patients, but especially these patients, in light of the known associations between CVD and BC. Expand
Coronary heart disease and mortality following a breast cancer diagnosis
TLDR
Better CVH appears to be protective against the development of CHD even among women who had received potentially cardiotoxic treatments, and attainment of ideal CVH is important not only for CHD and mortality outcomes among women diagnosed with breast cancer. Expand
Cardiovascular Disease Risk in Survivors of Breast Cancer
TLDR
The recent evidence about cardiovascular effects of breast cancer therapy and recommendations for their diagnosis and management during the cancer treatment continuum into survivorship are summarized. Expand
Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger
TLDR
Joining forces for combined cardiovascular and hemato-oncological preventive and research efforts will likely have synergistic, worldwide public health benefits. Expand
Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.
TLDR
The risk of CVD in patients with breast cancer is reviewed, providing an overview of the cardiac events associated with standard therapies for metastatic breast cancer and the current clinical recommendations relating to cardiac monitoring, and practical management strategies for oncologists are assessed. Expand
Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association
TLDR
Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. Expand
Cancer Survivorship and Subclinical Myocardial Damage: The Atherosclerosis Risk in Communities (ARIC) Study.
TLDR
Survivors of some cancers may be more likely to have elevated hs-cTnT than persons without prior cancer, and the excess burden of subclinical myocardial damage in this population may not be fully explained by traditional CVD risk factors. Expand
The breast cancer patient in the cardioncology unit.
TLDR
In this review, the advantages of a cardioncology approach in terms of risk stratification, monitoring for early diagnosis, prevention, and early treatment of cardiotoxicity are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 443 REFERENCES
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology
TLDR
Research and clear surveillance guidelines are needed to aid the practicing clinician in CVD prevention in breast cancer survivors and long-term consequences on the heart that are secondary to therapy are a major concern. Expand
Cardiovascular Disease Mortality Among Breast Cancer Survivors
TLDR
Breast cancer survivors are at greater risk for CVD-related mortality compared with women without breast cancer and this increase in risk is manifested approximately 7 years after diagnosis. Expand
Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer
TLDR
A majority of CVD medications evaluated in this study appear safe with respect to SBCE, but ACEI and BB use warrant further evaluation. Expand
Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors
TLDR
Clinical research is needed to determine whether exercise is a feasible and effective nonpharmacological treatment to reduce cardiovascular morbidity and mortality in breast cancer survivors, to identify the cancers for which it is effective, and to determine the optimal exercise dose. Expand
Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors
TLDR
The multidisciplinary prospective surveillance system proposed elsewhere in this supplement would allow for earlier detection of cardiotoxicity from treatment and may improve monitoring of cardiovascular health in the growing population of breast cancer survivors. Expand
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
TLDR
To identify those individuals at high risk of cardiac toxicity, baseline measurement of LV ejection fraction (LVEF) is recommended by the American College of Cardiology and American Heart Association as standard of care for all breast cancer patients being considered for potentially cardiac-toxic treatment regimens. Expand
Comorbidities and cardiovascular disease risk in older breast cancer survivors.
TLDR
Results suggest that long-term prognosis in breast cancer patients is affected by management of preexisting conditions, and assessment of comorbid conditions and effective management of diabetes and hypertension in older breast cancer survivors may lead to longer overall survival. Expand
Cardiovascular Disease After Aromatase Inhibitor Use.
TLDR
The risk of the most serious cardiovascular events (cardiac ischemia or stroke) was not elevated in AI-only users compared with tamoxifen users, but the finding that other CVD events combined were greater in AI users requires further study. Expand
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
TLDR
Long-term adjuvant anastrozole treatment resulted in significantly fewer thromboembolic and cerebrovascular events and a similar incidence of ischemic cardiovascular events compared with tamoxifen, and the third-generation aromatase inhibitors have demonstrated an improvement in efficacy and tolerability over previous treatments. Expand
Physical activity and breast cancer prevention.
TLDR
It is likely that physical activity is associated with decreased breast cancer risk via multiple interrelated biologic pathways that may involve adiposity, sex hormones, insulin resistance, adipokines, and chronic inflammation. Expand
...
1
2
3
4
5
...